Abstract Familial adenomatous polyposis [FAP (OMIM 175100)] is an autosomal dominant colorectal cancer predisposition syndrome characterized by hundreds to thousands of colonic polyps and, if untreated by a combination of screening and/or surgical intervention, a »99% lifetime risk of colorectal cancer. A subset of FAP patients develop an attenuated form of the condition characterized by lower numbers of colonic polyps (highly variable, but generally less than 100) and a lower lifetime risk of colorectal cancer, on the order of 70%. We report the diagnosis of three attenuated FAP families due to a 1.4-kb deletion within intron 14 of APC, originally reported clinically as a variant of unknown signiWcance (VUS). Sequence analysis suggests that this arose through an Alu-mediated recombination event with a locus on chromosome 6q22.1. This mutation is inherited by family members who presented with an attenuated FAP phenotype, with variable age of onset and severity. Sequence analysis of mRNA revealed an increase in the level of aberrant splicing of exon 14, resulting in the generation of an exon 13-exon 15 splice-form that is predicted to lead to a frameshift and protein truncation at codon 673. The relatively mild phenotypic presentation and the intra-familial variation are consistent with the leaky nature of exon 14 splicing in normal APC. The inferred founder of these three families may account for as yet undetected aVected branches of this kindred. This and similar types of intronic mutations may account for a signiWcant proportion of FAP cases where APC clinical analysis fails because of the current limitations of testing options.
Introduction
Familial adenomatous polyposis [FAP (OMIM 175100) ] is an autosomal dominant colorectal cancer predisposition syndrome characterized by hundreds to thousands of colonic polyps of the colonic epithelium. It has an average age of onset between the late teens and the early thirties, depending on the site of the mutation, and, in the absence of surgical intervention, a median age of colon cancer of 38 years (Cao et al. 2006; Friedl et al. 2001; Petersen et al. 1991) . AVected individuals also bear increased risk for extra-colonic malignancies, including gastric, duodenal, pancreatic, thyroid, and CNS cancers (Elkharwily and Gottlieb 2008; Galiatsatos and Foulkes 2006; Knudsen et al. 2003; Nieuwenhuis and Vasen 2007) . FAP is primarily caused by a constitutional mutation of the adenomatous polyposis coli (APC) gene. A subset of patients have a clinically attenuated presentation and course of disease progression, including lower numbers of polyps, generally less than 100 (Leppert et al. 1990; Lynch et al. 1990 Lynch et al. , 1992 Lynch et al. , 1993 ) and a lower lifetime risk of colon cancer (»70% in the absence of therapeutic intervention; Burt et al. 2004) . In this report, a family with an attenuated FAP (AFAP) phenotype was investigated for the possible causality of a complex deletion within intron 14 of APC. The deletion was originally detected by clinical genetic testing of the proband using Southern blot analysis, and reported as a variant of unknown signiWcance ("del portion intron 14"). Analysis of the mRNA demonstrated the association of the variant with reduced normal splicing of exon 14. Subsequently, two additional families with intron 14 deletions were referred to the study, and found to share the identical mutation, raising the possibility that this is a previously unrecognized founder mutation accounting for a large number of unidentiWed AFAP patients, among descendants dating back »6 generations.
Methods
This study was approved by the Institutional Review Board of the University of Utah. Informed consent was obtained from all research participants.
Research subjects
The three families (K7652, K495, and K485) were referred through research studies and medical centers in Missouri, Texas, and California. The proband of the original family (K7652) under investigation presented for genetic counseling and testing. She reported that she had a clinical diagnosis of AFAP, had a right hemi-colectomy at the age of 44 and underwent a further partial colectomy at the age of 66. Cancer history in extended family was reported by the proband and her brother, and conWrmed when possible by other enrolled family members and available medical records.
Genetic testing
Genomic DNA for research was extracted from fresh blood using Puregene ® DNA PuriWcation Kit, Gentra Systems (Minneapolis, MN, USA) according to manufacturer's protocols. PCR ampliWcation of genomic DNA [spanning nucleotides c.1862-c.1959-529 according to established  nomenclature guidelines (den Dunnen and Antonarakis  2000) as recently updated at http://www.hgvs.org/mutnomen/ recs-DNA.html] was performed using primers, APC exon 14 Forward (5Ј-CTTACCGGAGCCAGACAAAC-3Ј) and APC intron 14 Reverse (5Ј-GCCATCCTTCTTACGA GTGC-3Ј). Standard PCR conditions were followed, using PrimeStar Enzyme (Takara Bio Inc. Otsu, Shiga, Japan) with a PCR cycle of 98°C for 10 s, 60°C for 5 s, and 72°C for 2 min. PCR products were gel-puriWed using Qiagen QiaQuick ® PCR PuriWcation Kit #28104 (Valencia, CA, USA) according to the manufacturer's protocols. Sequence reactions were performed in both directions on gel-puriWed PCR products using APC exon 14 Forward and APC intron 14 Reverse primers. Reaction products were run on Applied Biosystems 3730XL capillary sequencer.
Analysis of mRNA RNA was extracted from EBV-transformed lymphoblasts using TRIZOL ® reagent according to manufacturer's protocol (Invitrogen Carlsbad, California, USA). cDNA was generated using the random hexamer protocol of SuperScript™ III First-StrandKit # 18080-051 (Invitrogen Carlsbad, California, USA), and PCR products were generated from the APC cDNA from coding nucleotides 1688-2099 using primers, APC 13 Forward (5Ј-TGCGAGAAGTTG GAAGTGTG-3Ј) and APC 15 Reverse (5Ј-TCCCAT AATGC TTCCTGGTC-3Ј). Standard PCR conditions were followed, using 2.5 mM MgCl 2 and an annealing temperature of 58°C. Sequence reactions were performed in both directions on gel-puriWed PCR products using APC 13 Forward and APC 15 Reverse primers. Reaction products were run on an Applied Biosystems 3730XL capillary sequencer. Sequence traces were compiled and aligned using Sequencher™ DNA Sequence Assembly Software, version 4.8, Build 3767 (Gene Codes Corporation, Ann Arbor, MI, USA).
Haplotype analysis
Genomic DNA was genotyped by PCR ampliWcation at four short tandem repeat (STR) loci D5S2027, D5S2501, D5S346, and D5S421 which span the APC locus (http:// genome.ucsc.edu) using published primer and reaction conditions (Schwab et al. 2008) . Reaction products were run on Applied Biosystems 3730XL capillary sequencer. Allele frequencies used to calculate the probability of inheriting the speciWc haplotype were based on those reported by the CEPH genotype database browser V2.1 http://www.cephb. fr/en/cephdb/search.php, derived from a minimum of 27 unrelated Caucasian individuals from eight kindreds (NIH/ CEPH Collaborative Mapping Group 1992).
Results

Clinical presentation
The phenotypic information collected on the available family members of each kindred is detailed in Table 1 and on the pedigree in Fig. 1 , including cancer, the presence or absence of adenomatous polyps, surgeries, and the age at the time of observation.
The proband of K7652 (IV-3) had more than 36 polyps detected by successive colonoscopies at regular intervals, including those noted at her hemi-colectomy at age 44. She underwent an additional partial colectomy at the age of 66 at which time numerous adenomas were noted. Her mother (III-9) was reported to have had several polyps at the time of her subtotal colectomy at the age of 64, but medical records have since been destroyed. The proband's brother, IV-6, had one adenoma at the age of 48, and none at the age of 59, as veriWed by medical records. Oral family history included reports that the proband's maternal grandfather, several of his siblings, his nephew and his mother had colon cancer and/or polyps; however no medical records are available. The proband's sister, IV-5 was reported and conWrmed to have died from complications of colon cancer at the age of 36. This sister's daughter (V-3) had a colonoscopy at the age of 42 which showed the presence of a single small rectal tubular adenoma (<5 mm). Other enrolled individuals on whom medical records were available were conWrmed to be adenoma-free at the ages noted.
Limited family history was available for the proband of K495, and no expansion was possible. The proband, previously reported as MDA046 (Su et al. 2000) , was diagnosed with colon cancer at 50 and died at 52, reported a mother who died of colon cancer at 70, and a maternal family history of one aunt and one cousin who were each reported to have had colectomies. No conWrming records were available.
The proband of K485 was diagnosed with adenocarcinoma, conWrmed by pathology reports at the age of 44 and died at 45. Family history included a father who underwent a hemi-colectomy in his Wfties and a paternal grandfather who died of colon cancer and who was reported at autopsy to have had multiple polyps and metastasized abdominal cancer at the time of death at the age of 60. The proband's daughter was conWrmed by pathology records to have had multiple tubular adenomas by successive colonoscopies by age 19.
Germline genetic changes
The original indication for the research study was the variant, determined by Southern blot analysis of the APC gene from peripheral blood, initially reported as a deletion of a portion of intron 14, using the commercially available COLARIS AP ® genetic test (Myriad Genetic Laboratories, Inc.). Full APC sequence analysis, as well as MUTYH testing for the two common mutations (Y179C; c.536A>G and G396D; c.1187G>A) was included in the test; no mutations were found.
Under a research protocol, genetic testing for the deletion was performed on blood samples from the proband, IV-3, her mother, III-9, her unaVected siblings, IV-1, and IV-6, as well as her daughters V-1 and V-2, and a niece V-3, and nephew V-4, through her deceased aVected sibling IV-5. PCR ampliWcation from exon 14 to the distal portion of intron 14 resulted in the predicted fragment of 2 kb in unrelated and unaVected related controls (Fig. 2a) . The deletion identiWed in the aVected proband through clinical genetic testing was veriWed to be approximately 1.4 kb, resulting in a 0.5-kb product. Sequence analysis of this 0.5-kb product conWrmed that the deletion was entirely within intron 14; c.1958 + 28_1958 + 1660 (Fig. 2b) .
Direct sequence analysis revealed a complex insertiondeletion event, resulting from the exchange of an Alu-repetitive element-derived »200-bp insertion originating from chromosome 6q22.1, for a 1633-bp deletion within APC (Fig. 3) . The insertion shared homology at the proximal end with the proximal end of the deleted sequence and at the distal end with the distal end of the deletion. This insertion contained a 114-bp portion of an Alu-containing repetitive element sequence with 100% identity to an Alu-containing repetitive element located on chromosome 6, preceded by a 87-107-bp run of Ts. The long runs of Ts that resulted from the recombination event represent a technical challenge for the polymerizing and sequencing enzymes to replicate, resulting in slippage that prevents accurate sequence reads downstream of the recombination.
The results showed that the proband of K7652 and her clinically aVected mother carried the insertion-deletion, while three clinically unaVected Wrst-degree relatives did not. Analysis of the proband of K495 and daughter of the K485 proband also carried the identical insertion-deletion, while unaVected K485 family members did not (Fig. 2a) .
mRNA analysis
To address the possible molecular consequence of the intronic deletion on mRNA splicing, PCR was performed on cDNA derived from mRNA from available individuals in K7652 and K485. Unrelated as well as clinically unaVected family members without the deletion in question served as negative controls. PCR ampliWcation from exon 13 to exon 15 resulted in a predicted product of 412 bp in all samples (Fig. 4a) . The same reaction also revealed a 197-bp product in the K7652 proband and her aVected mother, in addition to the normal-sized fragment of 412 bp also found in unaVected family members. Similar analysis of mRNA from the children of the K485 proband revealed identical results (not shown). Sequence analysis of the shorter product revealed a discrete deletion of exon 14 (Fig. 4b) . Consistent with previous reports, the shorter fragment was also identiWed at low levels in the unrelated and unaVected controls representing a minor alternative splice product (Bala et al. 1996 (Bala et al. , 1997 Montera et al. 2001) . Deletion of exon 14 results in a predicted translational frameshift and protein truncation at codon 673 of the normal open reading frame, approximately 20 codons into exon 15. This results in a truncated product that lacks all of the -catenin, microtubule, and EB-1-binding domains.
Haplotype analysis
Haplotyping was used to determine the likelihood that the K495 proband, originally identiWed by Su et al. (2000) , and K485 proband shared identity by descent at the APC locus with K7652. The disease-associated haplotype is shown in Fig. 1 as alleles 5 (D5S2027), 5 (D5S2501), 9 (D5S346), and 7 (D5S421). By using the published CEPH allele frequencies of STR alleles at the four loci used, the population frequency of the deletion-carrying haplotype in the family was calculated to be one in 283 (giving an eVective P value of 0.0035). Both the K495 and K485 aVected family members were found to share the mutation-associated haplotype of the K7652 proband, suggesting that all three kindreds descend from a common founder (Fig. 1 ). The precise relationship was not identiWed, but oral family histories and genealogic data from familysearch.org (http://www.familysearch.org) revealed that founders of K7652 and K485 were born and raised in Randolph County, IL in the 1830s supporting a common ancestral link.
Discussion
We describe a family where an attenuated FAP (AFAP) phenotype is transmitted through several generations in which an APC allele, with a large intronic insertion-deletion, tracks with the phenotype (Fig. 1) . No other diseasecausing mutations were found within APC of the proband, either by southern blot or by sequence analysis. RT-PCR analysis reveals signiWcantly enhanced prevalence of a transcript corresponding by sequence analysis to a discrete deletion of exon 14 in individuals inheriting the intronic deletion. We conclude that this deletion is the causative genetic determinant of AFAP in this family. A similar isolated case was noted previously in which an apparently identical deletion within intron 14, (described as 27-1627 bp downstream of exon 14) was shown to be associated with colonic polyposis (Su et al. 2000) . This same sequence was conWrmed in our kindred. We determined the breakpoint to be ¸21 bp downstream of this reported case, based on two further nucleotide diVerences between the inserted sequences. The remaining discrepancy was reconciled with the original normal intronic sequence by diVerences in the numbers of T residues detected in two runs of Ts, as reported by RefSeq RNA alignments against the human genome using blat, to generate the best consensus sequence (Kent 2002; Pruitt et al. 2007 ) and sequence alignment analysis run by ClustalW2 software (Larkin et al. 2007 ). Accordingly, we use the nomenclature APC c.1958 + 28_1958 + 1660conNT_025741.14:c. , as updated at http://www.hgvs.org/mutnomen/recs-DNA.html#indel. A third family, also sharing identical deletion and haplotype inheritance was also identiWed. Genealogical data revealed founders of K7652 and K485 share a common ancestor residing in Illinois around the 1830s. We hypothesize that the deletion was originally mediated by imperfect internal Alu-mediated recombination within intron 14, similar to that reported by Cao et al. (2001) , in their analysis of a »6-kb deletion that was shown to Xank exon 14 of APC. There are three such repeats located within intron 14, and the proximal deletion boundary coincides with the proximal boundary of the proximal T n -containing Alu-containing repeated element from chromosome 6 (Fig. 3) . The distal repeat, which also includes an Alu element, was replaced in the recombined allele with the highly related, but not identical chromosome 6 repeat. The long runs of Ts that resulted from the original recombination not only represent a technical challenge for the polymerizing and sequencing enzymes to replicate, resulting in slippage that prevents accurate sequence reads downstream of the recombination but may also contribute to an expansion repeat element within the newly generated allele that is subject to expansion with successive generations and may contribute to the phenotype by inXuencing the spatial relationships of local splicing signals.
Splice signals
The mutation identiWed is unusual in that it is entirely intronic and relatively distant from known acceptor or donor splice signals. The intron 14 deletion ablates consensus signals for two splicing proteins, SRp40 and SC35 (Cartegni et al. 2003; Smith et al. 2006) . Although alternative signals can be found in the sequence that remains, they are further from exon 14, weaker in consensus strength and oriented diVerently with respect to each other, possibly 
Phenotype
Several cases of deleterious mutations in exon 14 have been reported, and include both FAP and attenuated FAP patients and families (De Rosa et al. 2003; Enomoto et al. 2000; Ficari et al. 2000; Montera et al. 2001; Scarano et al. 1997; Won et al. 1999) . The classic FAP phenotypic cases appear to preclude normal translation of full-length APC, by the generation of a frameshift or stop codon, or by ablating normal splicing (Goncalves et al. 2009 ) while the attenuated cases tend to be splice variants that would be predicted to change the balance of translated splice forms. The mutation described here results in a predominant exon 13-exon 15 splice-form that is predicted to lead to a translational frameshift and protein truncation product at what would normally be codon 673 in the APC transcript. It is clear from our work and that of others' that alternative splicing of exon 14 is a normal low-level event in colonic epithelium as well as in peripheral blood lymphocytes (Aretz et al. 2004; Bala et al. 1997; Venesio et al. 2007 ). Some reports have suggested a possible functional role for such alternate splice forms in normal regulation of gene expression, perhaps by modulating total transcript or full length protein levels (Sulekova et al. 1995) . This low-level alternate transcript generates an outof-frame exon 13-exon 15 fusion. Other examples of attenuated FAP kindreds have been reported in which the penetrance is variable, including one with a 2-bp deletion in exon 4 (Burt et al. 2004; Neklason et al. 2008) , in which 15% of genetically conWrmed cases have ·2 polyps at the time of baseline colonoscopy (ages 19-67 years; unpublished results). This may explain the normal colonic phenotype of V-1 in K7652 at the age of 33. At the other end of the spectrum, a number of demonstrated or inferred deletion carriers died at young ages of colon cancer; V-1, in K485 at the age of 44, IV-1, in K495 at the age of 50, and IV-5 in K7652, who most likely inherited her mother's deletion, at the age of 36. However, this is also consistent with the reported lifetime risk of colon cancer in AFAP kindreds of 70-80% (Burt 2007; Burt et al. 2004; Hernegger et al. 2002; Knudsen et al. 2003) . Independently of the familial predisposition, the background population risk confounds the risk assessment of this allele; three individuals who do not share the deletion or the haplotype, III-11, IV-6, and V-3, were reported to have colon cancer at 63 years, a single adenoma of the ascending colon at 48 years and a single adenoma of the rectum at 42 years, respectively. AGCTGGGACTACAGGCATGCACTACCATGCCCGGCTAATTTTT-GTATTTTTAGTAGAGA **************** * * *** *************** **************** Chr 6 CGGGGTTTCACCTTGTTAGCCAGGATGGTCTCGATCTCCTGACCTC--GTGATCCACCCG Intron 14 CAGGGTTTCACCATGTTGGCCAGGCTGGTCTTGATCTCCTAATCTCAGGTGATCCGCCTG * ********** **** ****** ****** ******** * *** ******* ** * Chr 6
CCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACCGCACCCGGCCTTT--CAC Intron 14 CCTCAGCCTCCTAAAGTGCTGGGATTACAGGCATGAGCCACTGTGTCTGGCCAAGAGCAC **** ****** ******************** ******** * * **** *** normal mutant TTGAGACGGAGTCTCGCTCTGTTGCCCAGGCCGGACTGCGGACTGCAATGGCGCAATCTC GAGATGGAGTCTCACTCTGTTGTCCAGGTTGGAGTGC-------AGTGGTGTGATCTC ****** ******** ******** ***** *** *** * *** * ***** GGCTCACTGCAAGCTCCGCTTCCTGGGTTCACGCCATTCTCCTGCCTCAGCCTCCCGAGT GGCTCACTGCAACCTCTGCCTCCCAAGTG------ATTCTCCTGGCTCAGCCTCCTGAGT ************ *** ** *** ** ********* ********** ****
VUS reclassiWcation
ReclassiWcation of variants of unknown signiWcance (VUS) as either deleterious or benign is an important process for good medical management. VUS present challenges at several levels. For patients and their families, they are particularly frustrating and often diYcult to understand (Frost et al. 2004 ). For genetic counselors and physicians, they can represent a failure; they neither provide an answer for future management choices nor rule one option out, justifying proceeding in a diVerent direction for answers. For basic researchers, they challenge the status quo; the paradigm within which mutations can be rationally classiWed into "deleterious" versus "benign"; variants along the continuum of human genetic variation. The proportions of genetic changes classiWed as VUS varies from one gene to another, depending on the mutational spectrum and function of the encoded protein. Nevertheless, although it is becoming more clear that some alleles may defy the binary classiWcation, depending on other co-factors to co-determine their penetrance, it remains a core feature of genetic services that when the bar of technological challenges is lowered and these VUS can be properly classiWed, satisfying answers may be provided to the families and care providers. Previous reports have clariWed the contributions of APC exonic and splice-junction variants to disease (Aretz et al. 2004; Goncalves et al. 2009; Kaufmann et al. 2009 ).
The mechanism of mutation in the kindreds examined in this study appears to fall into a small but growing class of rearrangement mutations in colon cancer predisposition genes (Halling et al. 1999; McCart et al. 2006; NystromLahti et al. 1995; Yanaba et al. 2008) . Nevertheless, and despite its apparent nature as a founder mutation, several CLIA-certiWed genetic testing laboratories that oVer genetic testing for APC mutations reported not having found this mutation in their records (Baylor College of Medicine Medical Genetics Laboratories, Mayo Clinic Molecular Genetics Laboratory; University of Pennsylvania School of Medicine Genetic Diagnostic Laboratory); however, with the exception of Myriad Genetic Laboratories, Inc., their testing methodologies, including the multiplex ligationdependent probe ampliWcation (MLPA) deletion assays, would not detect this mutation. The haplotyping and genealogical evidence suggests that the three kindreds may share a common ancestor dating back to the mid-1800s and may account for unidentiWed cases of inherited rather than sporadic polyposis and/or colon cancer.
This study is particularly important from both a clinical and research perspective, and illustrates the beneWcial synergy between these two components of translational medicine. As for most genetic conditions, mutation detection in FAP and AFAP patients is incomplete using the technologies applied by clinical testing laboratories. Intronic mutations are largely ignored, undetected, and/ or uncharacterized beyond the splice junction, but constitute an important clinical subset that would beneWt from complete and accurate evaluation oVered from a research platform. Detection and characterization of this speciWc intron 14 mutation is important in that it (1) links three previously independent cases to a common founder dating back to the 1800s and suggests the presence of many more aVected descendents, (2) describes an Alu-mediated recombination that may underlie other APC intron deletions, and (3) assigns the attenuated FAP phenotype to mutations that cause exon 14 to be spliced out. In the future it will be important to evaluate the subset of FAP and AFAP patients that are mutation-negative for APC splice defects and determine what proportion may be attributed to this mechanism.
